Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke
Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench...
Gespeichert in:
Veröffentlicht in: | Free radical biology & medicine 2013-09, Vol.62, p.26-36 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 36 |
---|---|
container_issue | |
container_start_page | 26 |
container_title | Free radical biology & medicine |
container_volume | 62 |
creator | Speer, Rachel E. Karuppagounder, Saravanan S. Basso, Manuela Sleiman, Sama F. Kumar, Amit Brand, David Smirnova, Natalya Gazaryan, Irina Khim, Soah J. Ratan, Rajiv R. |
description | Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases.
[Display omitted]
► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke. |
doi_str_mv | 10.1016/j.freeradbiomed.2013.01.026 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4327984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0891584913000361</els_id><sourcerecordid>1412161643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</originalsourceid><addsrcrecordid>eNqNkc9u1DAQhyMEotvCK4AlLlwS_Cd2HJCQUNVSpEocoGfL64x3vSTxYjvV5tYH4BHKy_VJ8GpLRW-cRpa_-WY0v6J4Q3BFMBHvNpUNAEF3S-cH6CqKCaswqTAVT4oFkQ0ra96Kp8UCy5aUXNbtUXEc4wZjXHMmnxdHlLFGYEYXxa-Leet3Tpdu7Cbjlj0gq03yAW2D7-cerecu-N3c6wgR6YiSDitIEdmMjDAFn7kEJjk_ouWM7m5u9ZgfO9flenfzGw2QdI_MGnqdtfE9Og9-QBZCbk0-uqz0KKbgf8CL4pnVfYSX9_WkuDo_-356UV5-_fzl9NNlabgkqbQMOGWiobJppRFtIzpOpCUdE0bTRpvaSoMJbWtuZW15Y4g2rTFCYEmh5eyk-HjwbqdlvqCBMQXdq21wgw6z8tqpxz-jW6uVv1Y1o3lknQVv7wXB_5wgJjW4aKDv9Qh-iorUhBJBRM0y-uGAmuBjDGAfxhCs9nmqjXqUp9rnqTBROc_c_erfTR96_waYgdcHwGqv9Cq4qK6-ZQPH2dIwvl_g7EBAvui1g6CicTAa6FzIuanOu_9a5Q84kMln</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412161643</pqid></control><display><type>article</type><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</creator><creatorcontrib>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</creatorcontrib><description>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases.
[Display omitted]
► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</description><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2013.01.026</identifier><identifier>PMID: 23376032</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer disease ; animal models ; antioxidants ; Antioxidants - metabolism ; Antioxidants - therapeutic use ; chelating agents ; Chelating Agents - metabolism ; death ; Free radicals ; Humans ; Hypoxia ; Hypoxia-Inducible Factor 1 - antagonists & inhibitors ; Hypoxia-Inducible Factor 1 - metabolism ; Hypoxia-inducible factors ; Metal chelators ; Metals - metabolism ; Molecular Targeted Therapy ; Neurodegeneration ; Neuroprotective Agents - metabolism ; Neuroprotective Agents - therapeutic use ; neuroprotective effect ; Oxidative Stress ; Parkinson disease ; procollagen-proline dioxygenase ; Prolyl hydroxylases ; stroke ; Stroke - drug therapy ; Stroke - enzymology ; Stroke - pathology ; therapeutics ; Transcription</subject><ispartof>Free radical biology & medicine, 2013-09, Vol.62, p.26-36</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</citedby><cites>FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.freeradbiomed.2013.01.026$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23376032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Speer, Rachel E.</creatorcontrib><creatorcontrib>Karuppagounder, Saravanan S.</creatorcontrib><creatorcontrib>Basso, Manuela</creatorcontrib><creatorcontrib>Sleiman, Sama F.</creatorcontrib><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Brand, David</creatorcontrib><creatorcontrib>Smirnova, Natalya</creatorcontrib><creatorcontrib>Gazaryan, Irina</creatorcontrib><creatorcontrib>Khim, Soah J.</creatorcontrib><creatorcontrib>Ratan, Rajiv R.</creatorcontrib><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><title>Free radical biology & medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases.
[Display omitted]
► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</description><subject>Alzheimer disease</subject><subject>animal models</subject><subject>antioxidants</subject><subject>Antioxidants - metabolism</subject><subject>Antioxidants - therapeutic use</subject><subject>chelating agents</subject><subject>Chelating Agents - metabolism</subject><subject>death</subject><subject>Free radicals</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia-Inducible Factor 1 - antagonists & inhibitors</subject><subject>Hypoxia-Inducible Factor 1 - metabolism</subject><subject>Hypoxia-inducible factors</subject><subject>Metal chelators</subject><subject>Metals - metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>Neurodegeneration</subject><subject>Neuroprotective Agents - metabolism</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>neuroprotective effect</subject><subject>Oxidative Stress</subject><subject>Parkinson disease</subject><subject>procollagen-proline dioxygenase</subject><subject>Prolyl hydroxylases</subject><subject>stroke</subject><subject>Stroke - drug therapy</subject><subject>Stroke - enzymology</subject><subject>Stroke - pathology</subject><subject>therapeutics</subject><subject>Transcription</subject><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQhyMEotvCK4AlLlwS_Cd2HJCQUNVSpEocoGfL64x3vSTxYjvV5tYH4BHKy_VJ8GpLRW-cRpa_-WY0v6J4Q3BFMBHvNpUNAEF3S-cH6CqKCaswqTAVT4oFkQ0ra96Kp8UCy5aUXNbtUXEc4wZjXHMmnxdHlLFGYEYXxa-Leet3Tpdu7Cbjlj0gq03yAW2D7-cerecu-N3c6wgR6YiSDitIEdmMjDAFn7kEJjk_ouWM7m5u9ZgfO9flenfzGw2QdI_MGnqdtfE9Og9-QBZCbk0-uqz0KKbgf8CL4pnVfYSX9_WkuDo_-356UV5-_fzl9NNlabgkqbQMOGWiobJppRFtIzpOpCUdE0bTRpvaSoMJbWtuZW15Y4g2rTFCYEmh5eyk-HjwbqdlvqCBMQXdq21wgw6z8tqpxz-jW6uVv1Y1o3lknQVv7wXB_5wgJjW4aKDv9Qh-iorUhBJBRM0y-uGAmuBjDGAfxhCs9nmqjXqUp9rnqTBROc_c_erfTR96_waYgdcHwGqv9Cq4qK6-ZQPH2dIwvl_g7EBAvui1g6CicTAa6FzIuanOu_9a5Q84kMln</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Speer, Rachel E.</creator><creator>Karuppagounder, Saravanan S.</creator><creator>Basso, Manuela</creator><creator>Sleiman, Sama F.</creator><creator>Kumar, Amit</creator><creator>Brand, David</creator><creator>Smirnova, Natalya</creator><creator>Gazaryan, Irina</creator><creator>Khim, Soah J.</creator><creator>Ratan, Rajiv R.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130901</creationdate><title>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</title><author>Speer, Rachel E. ; Karuppagounder, Saravanan S. ; Basso, Manuela ; Sleiman, Sama F. ; Kumar, Amit ; Brand, David ; Smirnova, Natalya ; Gazaryan, Irina ; Khim, Soah J. ; Ratan, Rajiv R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c581t-f3e5236728798c6976d518f1d36ca27ac4f8c012945f84f57c1ac9cc66082e953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer disease</topic><topic>animal models</topic><topic>antioxidants</topic><topic>Antioxidants - metabolism</topic><topic>Antioxidants - therapeutic use</topic><topic>chelating agents</topic><topic>Chelating Agents - metabolism</topic><topic>death</topic><topic>Free radicals</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia-Inducible Factor 1 - antagonists & inhibitors</topic><topic>Hypoxia-Inducible Factor 1 - metabolism</topic><topic>Hypoxia-inducible factors</topic><topic>Metal chelators</topic><topic>Metals - metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>Neurodegeneration</topic><topic>Neuroprotective Agents - metabolism</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>neuroprotective effect</topic><topic>Oxidative Stress</topic><topic>Parkinson disease</topic><topic>procollagen-proline dioxygenase</topic><topic>Prolyl hydroxylases</topic><topic>stroke</topic><topic>Stroke - drug therapy</topic><topic>Stroke - enzymology</topic><topic>Stroke - pathology</topic><topic>therapeutics</topic><topic>Transcription</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Speer, Rachel E.</creatorcontrib><creatorcontrib>Karuppagounder, Saravanan S.</creatorcontrib><creatorcontrib>Basso, Manuela</creatorcontrib><creatorcontrib>Sleiman, Sama F.</creatorcontrib><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Brand, David</creatorcontrib><creatorcontrib>Smirnova, Natalya</creatorcontrib><creatorcontrib>Gazaryan, Irina</creatorcontrib><creatorcontrib>Khim, Soah J.</creatorcontrib><creatorcontrib>Ratan, Rajiv R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Free radical biology & medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Speer, Rachel E.</au><au>Karuppagounder, Saravanan S.</au><au>Basso, Manuela</au><au>Sleiman, Sama F.</au><au>Kumar, Amit</au><au>Brand, David</au><au>Smirnova, Natalya</au><au>Gazaryan, Irina</au><au>Khim, Soah J.</au><au>Ratan, Rajiv R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke</atitle><jtitle>Free radical biology & medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>62</volume><spage>26</spage><epage>36</epage><pages>26-36</pages><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside. Hypoxia-inducible factor (HIF)-1α mediates a broad, evolutionarily conserved, endogenous adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective in a number of human neurological diseases and experimental models. In this review, we discuss molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further, we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal chelators on ferroptosis in vitro as well in animal models of neurological diseases.
[Display omitted]
► Adaptation to hypoxia has evolved over billions of years. ► HIF prolyl hydroxylases are sensors of hypoxia. ► Antioxidant “metal chelators” inhibit HIF prolyl hydroxylases. ► Prolyl hydroxylase inhibitors prevent death via HIF-dependent and independent paths. ► Prolyl hydroxylase inhibitors prevent ferroptosis and stroke.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23376032</pmid><doi>10.1016/j.freeradbiomed.2013.01.026</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0891-5849 |
ispartof | Free radical biology & medicine, 2013-09, Vol.62, p.26-36 |
issn | 0891-5849 1873-4596 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4327984 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Alzheimer disease animal models antioxidants Antioxidants - metabolism Antioxidants - therapeutic use chelating agents Chelating Agents - metabolism death Free radicals Humans Hypoxia Hypoxia-Inducible Factor 1 - antagonists & inhibitors Hypoxia-Inducible Factor 1 - metabolism Hypoxia-inducible factors Metal chelators Metals - metabolism Molecular Targeted Therapy Neurodegeneration Neuroprotective Agents - metabolism Neuroprotective Agents - therapeutic use neuroprotective effect Oxidative Stress Parkinson disease procollagen-proline dioxygenase Prolyl hydroxylases stroke Stroke - drug therapy Stroke - enzymology Stroke - pathology therapeutics Transcription |
title | Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoxia-inducible%20factor%20prolyl%20hydroxylases%20as%20targets%20for%20neuroprotection%20by%20%E2%80%9Cantioxidant%E2%80%9D%20metal%20chelators:%20From%20ferroptosis%20to%20stroke&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Speer,%20Rachel%20E.&rft.date=2013-09-01&rft.volume=62&rft.spage=26&rft.epage=36&rft.pages=26-36&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2013.01.026&rft_dat=%3Cproquest_pubme%3E1412161643%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412161643&rft_id=info:pmid/23376032&rft_els_id=S0891584913000361&rfr_iscdi=true |